MediPharm Labs and Cronos Group Enter Private Label Contract Manufacturing Agreement

MediPharm 实验室与 Cronos 集团签订私人标签合同生产协议

2019-09-19 19:42:00 GlobeNewswire

本文共2243个字,阅读需6分钟

TORONTO, Sept. 19, 2019 -- MediPharm Labs Corp. , a leader in specialized, research-driven cannabis extraction and cannabinoid isolation, is pleased to announce that it has signed a multi-year contract manufacturing agreement for the filling and packaging of vaporizer devices, subject to approval by Health Canada, for Cronos Group Inc.’s adult-use brand, COVE™. MediPharm Labs Inc. (“MediPharm”), a wholly-owned subsidiary of the Company, and a wholly-owned subsidiary of Cronos Group, entered into a CMA where MediPharm, utilizing its proprietary expertise and equipment, will provide filling of high-quality formulated concentrate, labelling and packaging services to exacting specifications at scale for Cronos Group. The initial term of the agreement is two years with an option for renewal. “On the eve of legalization of concentrates products in Canada, we are delighted to add Cronos Group, to our expanding turnkey white-label platform,” said Pat McCutcheon, CEO of MediPharm Labs. “By leveraging our specialized expertise, technology and industrial scale vape filling capabilities, we will assist Cronos Group in delivering high quality, purity assured and Health Canada approved, derivative products further advancing their industry leading reputation and enhancing the supply chain in this important new category.”    This is the second collaboration between the companies. In May 2019, MediPharm Labs signed a multi-year private label bulk resin supply agreement and a cannabis concentrate program agreement with Cronos Group. “Working with MediPharm Labs gives us the quality and optionality that we are looking for as we introduce our proprietary vape pen formulations,” said Mike Gorenstein, CEO of Cronos Group. “We are committed to continuing to the lead the industry responsibly as derivative products are introduced to the expanding Canadian marketplace.” About Cronos Group Inc. Cronos Group is an innovative global cannabinoid company with international production and distribution across five continents. Cronos Group is committed to building disruptive intellectual property by advancing cannabis research, technology and product development. With a passion to responsibly elevate the consumer experience, Cronos Group is building an iconic brand portfolio. Cronos Group’s portfolio includes PEACE NATURALS™, a global health and wellness platform, and two adult-use brands, COVE™ and Spinach™. To learn more about Cronos Group and its brands, please visit: www.thecronosgroup.com; www.peacenaturals.com; www.covecannabis.ca; www.spinachcannabis.com About MediPharm Labs Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical-like cannabis oil and concentrates and advanced derivative products utilizing a Good Manufacturing Practices designed facility and ISO standard built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with five primary extraction lines having 300,000 kg of annual processing capacity to deliver pure, safe and precisely dosed cannabis products for its customers. Through its wholesale, white label and tolling platforms, they formulate, process, package and distribute cannabis extracts and advanced cannabinoid-based products to domestic and international markets. As a global leader, the Company also completed its first commercial export to Australia in June 2019 and is nearing completion of its Australian extraction facility expected in 2019 with 75,000 kg of annual processing capacity. For further information, please contact:  Laura Lepore, VP, Investor Relations  Telephone: 705-719-7425 ext 216  Email: investors@medipharmlabs.com     Website: www.medipharmlabs.com CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION: This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things, the manufacturing, supply and legalization of vape pen devices and timing thereof, completion of MediPharm Labs’ Australian facility and timing thereof, and expected processing capacity of the Australian facility. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm Labs to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm Labs’ filings, available on the SEDAR website at www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.
2019年9月19日, TOROONTO —— MediPharm Labs Corp .是一家专业、研究驱动的大麻提取和大麻隔离领域的领先企业,该公司高兴地宣布,它已签署了一份关于蒸汽装置灌装和包装的多年合同制造协议,但需获得加拿大卫生部的批准。适用于 Cronos Group Inc .的成人使用品牌 COVE ™。 本公司全资子公司 MediPharm Labs Inc .(“ MediPharm ”)与 Cronos 集团的全资子公司 Cronos Group 订立 CMA , MediPharm 利用其专有技术和设备,将提供高质量的配方浓缩液的灌装。为 Cronos 集团提供严格规格的标签和包装服务。协议的初始期限为两年,可选择展期。 MediPharm Labs 首席执行官 Pat McCutcheon 表示:“在加拿大将浓缩产品合法化的前夕,我们很高兴将 Cronos Group 加入我们不断扩大的交钥匙白标平台。”“通过利用我们的专业知识、技术和工业规模的吸塑灌装能力,我们将协助 Cronos 集团提供高质量、高纯度的保证和加拿大卫生部批准的衍生产品,进一步提升其行业领先声誉,并在这一重要新类别中加强供应链。”这是一个很好的例子 这是两家公司之间的第二次合作。2019年5月, MediPharm Labs 与 Cronos Group 签署了为期多年的自有品牌散装树脂供应协议和大麻浓缩计划协议。 克罗诺斯集团首席执行官迈克•戈尔斯坦( Mike Gorenstein )表示:“与 MediPharm Labs 合作,为我们提供了我们正在寻找的品质和选择,因为我们引入了我们专有的 vape 笔配方。”“我们致力于以负责任的态度继续引领该行业,因为衍生品被引入不断扩大的加拿大市场。” 关于 Cronos 集团。 克罗诺斯集团是一家创新的全球性大麻公司,在五大洲拥有国际生产和销售。Cronos 集团致力于通过推进大麻研究、技术和产品开发来建设具有破坏性的知识产权。克罗诺斯集团热衷于负责任地提升消费者体验,正在打造一个标志性的品牌组合。Cronos Group 的产品组合包括全球健康和健康平台 PEACE NATUALS ™,以及两个成人使用品牌 COVE ™和 Spinach ™。欲了解更多有关 Cronos 集团及其品牌的信息,请访问: www.theronosgroup.com ; www.pearoinles.com ; www.covacanabis.ca ; www.spinachbiabis.com 关于药物实验室 MediPharm Labs 成立于2015年,专注于利用良好的制造规范设计的设施和 ISO 标准建造的洁净室生产纯化的、类似于制药的大麻油和浓缩物以及先进的衍生产品, MediPharm Labs 投资了一支专家、研究驱动的团队、最先进的技术,下游净化方法和专门建造的设施,有五条主要提取生产线,每年处理能力达30万公斤,为客户提供纯、安全和精确的大麻产品。通过其批发、白色标签和收费平台,他们制定、加工、包装和向国内外市场销售大麻提取物和先进的基于大麻的产品。作为全球领先企业,该公司还于2019年6月完成了对澳大利亚的首次商业出口,并接近于2019年完成其澳大利亚提取设施,年处理能力为75,000公斤。 欲了解更多信息,请联系: Laura Lepore ,副总裁,投资者关系电话:705-719-7425 ext 216 Email : investors @ medipharmabs.com 网站:\160; www.medipharmabs.com 有关资料的说明: 本新闻稿包含适用加拿大证券立法含义内的“前瞻性信息”和“前瞻性声明”(统称“前瞻性声明”)。除历史事实声明外,所有声明均为前瞻性声明,并基于截至本新闻稿发布之日的预期、估计和预测。任何涉及有关预测、预期、信念、计划、预测、目标、假设、未来事件或业绩的讨论的声明(通常但不总是使用“预期”或“不预期”、“预期”、“预期”或“不预期”、“计划”、“预算”、“预定”、“预测”、“估计”等短语)“相信”或“意图”或此类词语和短语的变化,或声明某些行动、事件或结果“可能”或“可能”、“会”、“可能”或“将”发生或实现)不是历史事实的陈述,可能是前瞻性陈述。在本新闻稿中,前瞻性陈述涉及,除其他外,制造,供应和合法化的 vape 笔设备及其时间,完成 MediPharm 实验室的澳大利亚设施和时间,以及预期的处理能力的澳大利亚设施。前瞻性陈述必须基于若干估计及假设,该等估计及假设虽然被认为合理,但受已知及未知风险、不明朗因素及其他可能导致实际结果及未来事件与该等前瞻性陈述所表达或隐含的重大差异的因素所规限。这些因素包括但不限于:一般商业、经济、竞争、政治和社会不确定性; MediPharm Labs 无法获得充足融资;延迟或未能获得监管批准;以及 MediPharm Labs 备案文件中讨论的其他因素。可在 SEDAR 网站 www.concer.com 上查阅。无法保证此类声明将被证明是准确的,因为实际结果和未来事件可能与此类声明中的预期存在重大差异。因此,读者不应过分依赖本新闻稿中的前瞻性陈述和信息。除法律规定外, MediPharm Labs 不承担任何义务,在信仰、观点、预测或其他因素发生变化时更新前瞻性陈述。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文